US pharma giant Pfizer (NYSE: PFE) has taken a 50% stake in a newly-formed company that will focus on the discovery and development of viral cancer vaccines.
Ignite Immunotherapy will work on targeted and proprietary next-generation intravenous oncolytic virus vaccines for the immunotherapy of cancer and says these biotherapeutics may be designed to be used in combination with immune checkpoint inhibitors.
"Our mission is to create intravenous oncolytic cancer vaccines that will be safe and highly effective in combination with immune checkpoint inhibitors"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze